Workflow
Thalys(603716)
icon
Search documents
塞力医疗更正参股子公司增资及投资公告股权结构
Xin Lang Cai Jing· 2025-09-18 08:50
Group 1 - The company issued a correction announcement regarding its investment in a subsidiary, which was initially disclosed on September 18 [1] - The correction involves changes in the shareholding structure of the target company post-acquisition, with "Cyrus Medical" reducing its stake from 49.00% to 41.00%, while "Weixin Biotechnology" increased its stake from 41.00% to 49.00% [1] - The company apologized for any inconvenience caused by the correction and stated it would enhance its information disclosure review process [1]
塞力斯医疗科技集团股份有限公司关于对参股子公司增资及实际控制人共同投资暨关联交易的对外投资公告
Investment Overview - The company plans to increase its investment in Wuhan Huajiyuan Biotechnology Development Co., Ltd. by 42.74 million yuan, raising its ownership from 30% to 41% [2][10] - The actual controller, Mr. Wen Wei, intends to acquire 10% of the shares from shareholder Sun Danping for 27.2 million yuan, with the total investment from both parties amounting to 69.94 million yuan [2][10] Transaction Details - The investment will be used for the clinical trials of a hypertension treatment vaccine project (HJY-ATRQβ-001) [8][19] - The transaction has been approved by the company's board and will be submitted for shareholder approval, with related parties abstaining from voting [3][27] Financial Impact - The investment is expected to support the development of the target company's business and align with the company's strategic transformation and optimization of its business structure [26] - The target company will be included in the company's consolidated financial statements as a controlled subsidiary in 2026 [2][26] Approval Process - The transaction has undergone necessary approvals from the board's independent directors and strategic committee, and it will be presented at the upcoming shareholder meeting [3][27] Risk Considerations - The target company is currently in the clinical stage of product development and has not yet generated profits, leading to uncertainties regarding future revenue and investment returns [4][29] - The investment may have limited short-term impact on the company's main business and cash flow [5][29]
塞力医疗拟4274万元增资武汉华纪元 推进治疗性降血压疫苗项目临床试验
Core Viewpoint - Seer Medical plans to increase its stake in Wuhan Huajiyuan Biotechnology by investing 42.74 million yuan, raising its ownership to 41% [1] - The company aims to advance the clinical trials of its therapeutic antihypertensive vaccine HJY-ATRQβ-001, which has received IND approval from the NMPA [2] Group 1: Investment and Ownership Changes - Seer Medical will invest a total of 69.94 million yuan in Wuhan Huajiyuan, including a 27.2 million yuan acquisition of a 10% stake from a shareholder [1] - Following the investment, Wuhan Huajiyuan will be consolidated into Seer Medical's financial statements as a subsidiary by 2026 [1] Group 2: Product Development and Clinical Trials - HJY-ATRQβ-001 is expected to provide a new treatment option for hypertension patients, with no similar drugs currently in clinical development globally [2] - The company aims to complete Phase I and IIa clinical trials within two years, followed by Phase IIb trials [1][2] Group 3: Financial Performance and Strategic Direction - Seer Medical reported a 40.2% decline in revenue to 584 million yuan in the first half of the year, with a net loss of 56.12 million yuan [2][3] - The company is undergoing a strategic transformation towards smart healthcare, which has temporarily impacted profits but is expected to support long-term growth [3] - Seer Medical's stock price has increased by 325% this year, reflecting strong market performance [3]
塞力医疗(603716.SH):向武汉华纪元增资4274.29万元
Ge Long Hui A P P· 2025-09-17 11:46
Core Viewpoint - The company, Saily Medical (603716.SH), has approved a capital increase in its subsidiary, Wuhan Huajiyuan, which will enhance its ownership stake and support the development of a therapeutic hypertension vaccine project [1] Group 1: Investment Details - The company plans to invest 42.7429 million yuan in Wuhan Huajiyuan, increasing its ownership from 30% to 41% [1] - The actual controller, Mr. Wen Wei, will acquire an additional 10% stake in Wuhan Huajiyuan for 27.2 million yuan, with other shareholders waiving their preemptive rights [1] - The total investment from the company and Mr. Wen Wei amounts to 69.9429 million yuan [1] Group 2: Strategic Implications - The capital increase will provide additional funding to Wuhan Huajiyuan, facilitating the clinical trials of the therapeutic hypertension vaccine (HJY-ATRQβ-001) [1] - This investment aligns with the company's strategic transformation plan, optimizing its business structure and enhancing core competitiveness [1] - The investment is expected to promote sustainable and steady development for the company [1]
塞力医疗(603716.SH)拟向武汉华纪元增资4274.29万元
智通财经网· 2025-09-17 11:37
Core Viewpoint - The company, Sely Medical (603716.SH), plans to increase its stake in Wuhan Huajiyuan by investing 42.7429 million yuan, raising its ownership to 41% [1] Investment Details - The actual controller, Mr. Wen Wei, intends to acquire 10% equity from shareholder Sun Danping for 27.2 million yuan, based on a post-investment valuation of 272 million yuan [1] - Other shareholders of Wuhan Huajiyuan have waived their preemptive rights regarding this equity transfer [1] - After the completion of the equity transfer, Mr. Wen Wei will delegate all voting rights corresponding to the 10% equity he holds to Sely Medical [1] Financial Implications - The total investment from the company and Mr. Wen Wei amounts to 69.9429 million yuan [1] - Wuhan Huajiyuan is expected to be included in the company's consolidated financial statements as a controlled subsidiary by 2026 [1] Strategic Alignment - This investment will provide additional financial support to Wuhan Huajiyuan, facilitating the clinical trials of its therapeutic antihypertensive vaccine project (HJY-ATRQβ-001) [1] - The move aligns with the company's strategic transformation plan, optimizing its business structure and enhancing core competitiveness [1] - The investment is positioned to promote sustainable and steady development for the company [1]
塞力医疗拟向武汉华纪元增资4274.29万元
Zhi Tong Cai Jing· 2025-09-17 11:35
Core Viewpoint - The company, Saily Medical (603716.SH), plans to increase its stake in Wuhan Huajiyuan by investing 42.74 million yuan, raising its ownership to 41% [1] Group 1: Investment Details - The actual controller, Mr. Wen Wei, intends to acquire 10% equity from shareholder Sun Danping for 27.2 million yuan, based on a post-investment valuation of 272 million yuan [1] - The total investment from the company and Mr. Wen Wei amounts to 69.94 million yuan [1] - Other shareholders of Wuhan Huajiyuan have waived their preemptive rights regarding the equity transfer [1] Group 2: Strategic Implications - The investment will provide additional funding to Wuhan Huajiyuan, supporting the development of its therapeutic hypertension vaccine project (HJY-ATRQβ-001) through various clinical trial phases [1] - This move aligns with the company's strategic transformation plan, optimizing its business structure and enhancing core competitiveness [1] - The target company is expected to be included in the company's consolidated financial statements as a controlled subsidiary by 2026 [1]
塞力医疗:拟4274万元增资武汉华纪元 推进疗性降血压疫苗(HJY-ATRQβ-001)项目各期临床试验
Mei Ri Jing Ji Xin Wen· 2025-09-17 11:11
Core Viewpoint - The company, Celery Medical (603716.SH), plans to increase its investment in its subsidiary, Wuhan Huajiyuan Biotechnology Development Co., Ltd., by 42.74 million yuan, which will raise its ownership stake to 41% [1] Group 1: Investment Details - The actual controller, Wen Wei, intends to acquire a 10% stake from shareholder Sun Danping for 27.2 million yuan, based on a post-investment valuation of 272 million yuan [1] - The total investment from the company and Wen Wei will amount to 69.94 million yuan [1] Group 2: Future Plans - The target company is expected to be included in the company's consolidated financial statements as a controlled subsidiary by 2026 [1] - All parties have agreed to actively promote the clinical trials for the therapeutic antihypertensive vaccine (HJY-ATRQβ-001) project, aiming to complete Phase I and Phase IIa clinical trials within two years, followed by the implementation of Phase IIb clinical trials [1]
塞力医疗(603716) - 塞力斯医疗科技集团股份有限公司拟增资所涉及武汉华纪元生物技术开发有限公司股东全部权益价值项目资产评估报告(中企华评报字【2025】第 6518 号)
2025-09-17 11:03
涉及武汉华纪元生物技术开发有限公司 股东全部权益价值项目 资产评估报告 中企华评报字(2025)第 6518 号 (共一册,第一册) 本报告依据中国资产评估准则编制 塞力斯医疗科技集团股份有限公司拟增资所 北京中企华资产评估有限责任公司 二〇二五年八月二十八日 | 报告编码: | 2411020110240401202500064 | | --- | --- | | 合同编号: | PG20251042732000 | | 报告类型: | 非法定评估业务资产评估报告 | | 报告文号: | 中企华评报字(2025)第6518号 | | 报告名称: | 塞力斯医疗科技集团股份有限公司拟增资所涉及武汉华纪元生物 技术开发有限公司股东全部权益价值项目 | | 评估结论: | 234,295,500.00元 | | 评估报告日: | 2025年08月28日 | | 评估机构名称: | 北京中企华资产评估有限责任公司 | | 签名人员: | 王晨煜 (资产评估师) 正式会员 编号:24000264 | | | 孙丽娟 (资产评估师) 正式会员 编号:24210011 | | | 王晨煜、孙丽娟实名认可 | | 声 | ...
塞力医疗(603716) - 关于对参股子公司增资及与实际控制人共同投资暨关联交易的对外投资公告
2025-09-17 11:01
关于对参股子公司增资及实际控制人共同投资 暨关联交易的对外投资公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 投资标的名称:武汉华纪元生物技术开发有限公司(以下简称"武汉华 纪元"或"目标公司"、"标的公司") 投资金额:截至本公告披露日,塞力斯医疗科技集团股份有限公司(以 下简称"公司"或"塞力医疗")持有武汉华纪元 30%的股权,本次公司计划 向武汉华纪元增资 4,274.29 万元,增资完成后,公司持有武汉华纪元股份比 例将增加至 41%。 证券代码:603716 证券简称:塞力医疗 公告编号:2025-082 债券代码:113601 债券简称:塞力转债 塞力斯医疗科技集团股份有限公司 同时,公司实际控制人温伟先生拟以增资后的估值2.72亿元,以2,720万 元收购武汉华纪元股东孙丹平10%的股权,标的公司其他股东已放弃优先认购 权。股权转让完成后,温伟先生承诺无偿将其持有的武汉华纪元10%的股权对 应的表决权全部委托给塞力医疗行使。本次交易公司及实际控制人温伟先生 合计出资6,994.29万元。目 ...
塞力医疗:9月16日召开董事会会议
Sou Hu Cai Jing· 2025-09-17 11:00
(记者 曾健辉) 免责声明:本文内容与数据仅供参考,不构成投资建议,使用前请核实。据此操作,风险自担。 每日经济新闻 每经AI快讯,塞力医疗(SH 603716,收盘价:30.68元)9月17日晚间发布公告称,公司第五届第二十 一次董事会临时会议于2025年9月16日在公司A栋C会议室以现场和通讯相结合的方式临时召开。会议审 议了《关于对参股子公司增资及与实际控制人共同投资暨关联交易的对外投资的议案》等文件。 2024年1至12月份,塞力医疗的营业收入构成为:商业占比97.09%,工业占比2.91%。 截至发稿,塞力医疗市值为64亿元。 每经头条(nbdtoutiao)——海拔4306米现"秦始皇密令",获官方"身份认定"!古文字学家刘钊:秦人 寻仙采药足迹确至青藏高原 ...